RPS20 and early-onset autosomal dominant Alzheimer disease: In the central nervous system, RPS20 serves as a prognostic marker in glioblastoma [35] and medulloblastoma [36] while also acting as a biomarker and potential therapeutic target in Alzheimer’s disease [37,38] and autoimmune hepatitis [39].